Boundless Bio, Inc. (BOLD) stock
Close on Nov 11, 2026Market cap $55.96MP/E –Yield –
Key statistics
Valuation at the latest close; fundamentals over fiscal , balances at Sep 30, 2026
Valuation
- Market cap
- $55.96M
- P/E ratio
- –
- Price to sales
- –
- Price to book
- 0.91
- Dividend yield
- –
- Free cash flow yield
- -102.58%
Fundamentals
- Net income
- -$55.50M
- EPS, diluted
- -$2.47
- Free cash flow
- -$57.40M
- Book value per share
- $2.70
- Diluted shares
- 23M
Trading
- Previous close
- $2.45
- Open
- $2.46
- Day's range
- $2.39 – $2.46
- Volume
- 10,831
- Average volume (20 days)
- 126,394
- Beta (5 years)
- 1.51
- 52-week range
- $0.96 – $3.16
- RSI (14 days)
- 48.2
- Volatility (1 year)
- 98.9%
- Relative volume
- 0.06×
- WACC
- 12.5%
On 2 of our idea lists: Net-nets, More cash than they're worth
Market cap history
Month-end market cap since 2024, using shares outstanding reported at the time
Total return vs. the S&P 500
Price change plus reinvested dividends, to the close on Nov 11, 2026. The S&P 500 is measured by the SPY fund.
| Period | BOLD | S&P 500 | Difference | BOLD per year | S&P 500 per year |
|---|---|---|---|---|---|
| 1 month | -2.8% | -2.4% | −0.4 pts | ||
| 3 months | -10.5% | -1.2% | −9.4 pts | ||
| Year to date | +105.0% | +12.3% | +92.7 pts | ||
| 1 year | +95.2% | +12.4% | +82.8 pts |
Four years at a glance
Fiscal years 2022 to 2025 and trailing twelve months, USD
Operating income
Net income
EPS, diluted
Free cash flow
Press releases
Releases Boundless Bio filed with the SEC as exhibits to Form 8-K or 6-K
- Update
- Update
- Results
- Results
- Results
- Results
About Boundless Bio
Pharmaceutical Preparations
Boundless Bio is a clinical-stage oncology company developing extrachromosomal DNA directed therapeutics to treat oncogene amplified cancers. Using its proprietary Spyglass platform, the company identifies synthetic lethal targets essential for extrachromosomal DNA function and designs small molecule therapies to inhibit them. Its lead product candidate, BBI-940, is an oral selective degrader targeting a kinesin involved in DNA segregation during mitosis, which entered a Phase 1 clinical trial for patients with certain types of breast cancer.
Company profile, executives and historyBoundless Bio stock: common questions
What is Boundless Bio's stock price?
BOLD closed at $2.46 on Nov 11, 2026, up 0.41% on the day. Over the past 52 weeks it traded between $0.96 and $3.16.
What is Boundless Bio's market cap?
Boundless Bio was worth $55.96M at the close on Nov 11, 2026: the share price times the diluted shares outstanding.
What is BOLD's P/E ratio?
Boundless Bio lost money over the twelve months to Sep 30, 2026 (diluted EPS -$2.47), so it has no meaningful P/E ratio.
Does Boundless Bio pay a dividend?
No. Boundless Bio has not paid a cash dividend over the last twelve months.
How has BOLD stock performed over the past year?
Including dividends, BOLD returned +95.2% over the past year, against +12.4% for the S&P 500.
How many BOLD shares are sold short?
1M shares were sold short at the latest FINRA report, 5.49% of the float, or 5.1 days of average trading volume.
Who are Boundless Bio's competitors?
Companies most similar to Boundless Bio by business, industry and size include BBOT, IDYA, PRLD, PHIO, TYRA.
See a number that looks wrong?